The non-profit La Jolla Institute for Allergy and Immunology said last week that it has licensed to MedImmune the intellectual property rights to a discovery that could serve as the basis for a new biologic treatment for asthma.

If MedImmune can develop and market a drug based on the discovery, it could be a financial boost to the La Jolla Institute, which established a dedicated tech-transfer department in 2007 as part of an institute-wide effort to diversify its revenue sources before funding from sole corporate sponsor, Kirin Pharma USA, dries up in 2010.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.